Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Anna Durbin, MD
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Principal Investigator - Kristen Pierce, MD
University of Vermont
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Center for Immunization Research, Johns Hopkins School of Public Health
Baltimore, Maryland, United States
- University of Vermont Medical Center
Burlington, Vermont, United States
- University of Vermont Vaccine Testing Center
Burlington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2015
- Primary completion
- 31 Oct 2015
- Completion
- 31 Oct 2015
- Last update posted
- 4 Apr 2016
- Registered enrollment
- 20
- Registry id
- NCT02450838
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.